HeartSciences Inc. Common Stock (HSCS)

FairStock Score: 49/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach HeartSciences as a Graham-style bargain hunter, and the numbers offer little comfort. The business sells AI-enhanced ECG products, but in fiscal Q1 2027, the quarter ended 2026-07-31, revenue was only $2,100 and net loss was $3.2M, with diluted EPS of -$0.86. Full-year filed figures show revenue of $18,600 in FY2024, ended 2024-04-30, then $4,350 in FY2025, ended 2025-04-30, and $4,319 in FY2026, ended 2026-04-30. Net losses were $6.6M, $8.8M, and $9.1M respectively. That is not a compounding machine; it is a cash-consuming startup. Trailing free cash flow is -$7.1M, a -48.0% FCF yield on a $14.8M market cap. The Piotroski F-Score is 3/9 and Altman Z-Score is -35.73, both pointing to financial fragility. Debt-to-equity is 1.46, so leverage adds risk. At the 2026-10-13 close of $3.09, the FairStock P/B is 44.14 and P/E is -1.12; with negative earnings, the P/E is not meaningful, but the P/B shows little asset backing. ROE is -1851.90% and ROCE is -116.44%, again FairStock calculations. I see no durable moat from the given facts: 14 employees, tiny revenue, no profits in the last four years, and no Lynch category. FairStock score is 49/100. The stock may be an option on AI-ECG adoption, but as a value investment it fails the tests of earnings, assets, and margin of safety.

In plain English: The company sells AI-enhanced heart ECG technology, but it is very small and losing money. Revenue has been tiny and losses continue, so the business looks weak. At $3.09 a share, the price looks expensive compared with its current sales and losses.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-07-31) · fiscal Q3 2026 10-Q (period ended 2026-01-31) · fiscal Q2 2026 10-Q (period ended 2025-10-31) · fiscal Q1 2026 10-Q (period ended 2025-07-31) · FY2026 10-K (period ended 2026-04-30) · FY2025 10-K (period ended 2025-04-30) · FY2024 10-K (period ended 2024-04-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer